Inquadramento e trattamento della BPCO (BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA)ASMaD
Presentazione a cura del Professor Andò Filippo - XII° Congresso Nazionale FIMeG 2018 - The Silver Tsunami: l'anziano fra appropriatezza e farmaeconomia
Inquadramento e trattamento della BPCO (BRONCOPNEUMOPATIA CRONICA OSTRUTTIVA)ASMaD
Presentazione a cura del Professor Andò Filippo - XII° Congresso Nazionale FIMeG 2018 - The Silver Tsunami: l'anziano fra appropriatezza e farmaeconomia
L'ipertensione polmonare:come diagnosticarla e trattarlaASMaD
Presentazione a cura del Dottor Carmine Dario Vizza - XII° Congresso Nazionale FIMeG 2018 - The Silver Tsunami: l'anziano fra appropriatezza e farmaeconomia
Quali sono i modelli sperimentali in volontari sani in grado di valutare l’attività farmacologica (PD) dei nuovi composti per estrapolare dati che consentano di conoscere meglio il farmaco e selezionare le dosi per gli studi in pazienti: aspetti scientifici ed etici.
CTEPH, Surgcal and Medical Therapy. Terapia Chirurgica e medicaCTEPH
This document summarizes the experience of pulmonary endarterectomy (PEA) at a hospital in Pavia, Italy. It describes that PEA is the primary treatment for chronic thromboembolic pulmonary hypertension (CTEPH), and has better long-term outcomes than lung transplantation. The Pavia center has performed over 357 PEAs since 1994 and has developed expertise in evaluating, diagnosing, and performing the surgery on CTEPH patients.
CTEPH, Surgical and Medical Therapy. CTEPH, Terapia Chirurgica e MedicaCTEPH
This document summarizes the experience of pulmonary endarterectomy (PEA) at a hospital in Pavia, Italy. It describes that PEA is the primary treatment for chronic thromboembolic pulmonary hypertension (CTEPH), which can be surgically treated to remove blockages in the pulmonary arteries. The hospital has performed over 357 PEAs and seen good outcomes with low mortality and technical failure rates when performed by experienced surgeons.
The document discusses the use of various imaging techniques for identifying chronic thromboembolic pulmonary hypertension (CTEPH) as the cause of pulmonary hypertension, including ventilation-perfusion (V/Q) scintigraphy, CT pulmonary angiography (CTPA), and pulmonary digital subtraction angiography (DSA). It summarizes the results of studies comparing the diagnostic accuracy of V/Q scintigraphy and CTPA to pulmonary angiography. V/Q scintigraphy has high sensitivity but moderate specificity, while CTPA has moderate sensitivity and high specificity. The combination of V/Q scintigraphy and CTPA can improve diagnostic accuracy for CTEPH when their results are considered together.
This document summarizes the post-operative management of patients undergoing pulmonary endarterectomy (PEA) surgery. It discusses strategies for mechanical ventilation and weaning from ventilation. It also covers management of hemodynamics like weaning from inotropes and vasopressors. The document notes potential post-operative complications and their treatment, including reperfusion pulmonary edema, pulmonary hemorrhage, infections, and heparin-induced thrombocytopenia. Effective anticoagulation and monitoring is also emphasized.
The document discusses chronic thromboembolic pulmonary hypertension (CTEPH) and its pathophysiology. It describes the core pathologic process as an imbalance between prothrombotic factors and disturbed thrombus resolution, leading to in situ thrombosis over thromboembolic lesions. It also discusses the BENEFIT trial which found that treatment with bosentan improved exercise capacity and hemodynamics in inoperable CTEPH patients. The CHEST trial then evaluated riociguat, a soluble guanylate cyclase stimulator, in inoperable or recurrent CTEPH patients and found improvements in pulmonary vascular resistance and other outcomes.
Valutazione Strumentale Funzionale del pazienta con CTEPH
1. La valutazione strumentale funzionale del paziente con IPCTE : SPIROMETRIA, EGA, D L co - Test da sforzo IPERTENSIONE POLMONARE E CARDIOCHIRURGIA ISA CERVERI FISIOPATOLOGIA RESPIRATORIA
29. NYHA class 0 50 100 0 50 100 I II III IV I II III IV I II III IV preop 3 mo 1 year 2 years 3 years 4 years Number of pts NYHA Class Preop vs postop values p<0.001
30. Cumulative survival at 5 years: 84% 0.00 0.25 0.50 0.75 1.00 0 12 24 36 48 60 Months NYHA class I-II NYHA class III-IV
32. Results PaO 2st (mm Hg) Months 0 3 12 24 36 48 50 60 70 80 Preop vs postop values p<0.001 PaO2st DLCO (% of predicted) Months 0 3 12 24 36 48 60 65 70 75 Preop vs postop values @ 1 y p<0.001 DLco Distance (m) Months 0 3 12 24 36 48 0 200 400 600 Preop vs postop values p<0.001 modified Bruce test
33.
34.
35.
Editor's Notes
capacità di diffusione della membrana theta volume capillare alveolare
15 15
Incapacità di sostenere uno sforzo fisico che il soggetto riteneva di poter compiere senza avvertire fatica.
Jin, Please find a proper adjective for point 1 : ) Hi baby: you can use what i put in. or you can say it is “quite good”, “”. I feel that just using the word excellent should be okay too, but it’s up to you.